SCAI Therapeutics Receives IND Approval for Phase 2 Clinical Trial of ‘VEGFR Eye Drops’ for Age-Related Macular Degeneration in Korea

SCAI Therapeutics announced on the 20th that it had received approval from the Ministry of Food and Drug Safety on the 11th for its Investigational New Drug (IND) application for a Phase 2 clinical trial of "SCAI-005" a VERGFR TKI drug in eye drop formulation, for the treatment of neovascular age-related macular degeneration (nAMD).

Original article source: BIOSPECTATOR(바이오스펙테이터)

Source link: 스카이, ‘VEGFR 점안액’ 황반변성 국내 2상 “IND 승인” - 바이오스펙테이터